Navigation Links
Coherus Biosciences Invited to Present at 2014 J.P. Morgan Annual Healthcare Conference
Date:1/7/2014

REDWOOD CITY, Calif., Jan 7, 2014 /PRNewswire/ -- Denny Lanfear, President and CEO of Coherus Biosciences, will present at the J.P. Morgan 32nd Annual Healthcare Conference on Wednesday, January 15 at the Westin St. Francis in San Francisco, CA., beginning at 4:30pm Pacific Standard Time. 

(Logo:  http://photos.prnewswire.com/prnh/20120507/SF01448LOGO)

"Coherus' upcoming presentation at the conference marks an important milestone for our Company.  This event will introduce Coherus Biosciences to a worldwide healthcare investor audience and reflects the good progress the Company has made with products and partnerships," stated Mr. Lanfear. "To date, Coherus has filed INDs on three products and completed partnership agreements in Asia, Latin America and Europe with major biopharma firms while retaining US rights on all its products. We believe that this progress distinguishes Coherus as the leading independent pure play biosimilar company."

About Coherus Biosciences

Founded in 2010, Coherus Biosciences is a leading pure play biosimilar platform Company headquartered in the San Francisco Bay Area. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases. Our vision is to increase global patient access to high quality, life changing biologic medications.  Coherus' global partnerships include top tier BioPharma companies in Europe, Asia, and Latin America who are pursuing the integrated development and commercialization of products representing over $35 billion in current global sales.  From conceptualization to commercialization, Coherus' unique business model leverages a strategic consortium of key service providers aligned through ownership and shared incentives.  Through these partnerships, the Company has built a capital efficient infrastructure capable of taking products from cell lines to approved labels. To date, Coherus has raised approximately $125 million from equity and non-dilutive licensing fees.  Existing investors include KMG Capital, Lilly Ventures, Sofinnova and Venrock. 

Coherus Biosciences Contact
George Montgomery
(650) 649-3567
gmontgomery@coherus.com


'/>"/>
SOURCE Coherus BioSciences
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
2. Coherus anuncia que CHS-0214 (biosimilar etanercept propuesto) supera punto final primario en decisivo estudio clínico farmacocinético
3. Coherus Biosciences als Präsentator zur J.P. Morgan Annual Healthcare Conference 2014 eingeladen
4. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
6. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
7. Neurocrine Biosciences Reports First Quarter 2012 Results
8. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
9. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
10. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
11. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... June 24, 2016  Consumers have taken a ... have placed more emphasis on patient outcomes. ... programs in the pharmaceutical industry have evolved beyond ... pharmaceutical companies are focusing on becoming more patient-oriented ... products and services that improve health. ...
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
Breaking Medicine News(10 mins):